H.F.M STEM CELLS
Live / Registered — Registered (as of 04 Apr 2023)
What this means for you
Registered since 04 Apr 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79311220
- Registration number
- 7014490
- Mark type
- Stylized text
- Filed
- 21 Dec 2020
- Published for opposition
- 17 Jan 2023
- Registered
- 04 Apr 2023
- Attorney of record
- Sean K. Owens
Goods and services
- Class 001 — Chemicals: Stem cells for scientific or research use; cell growth media for growing cells for scientific use
- Class 005 — Pharmaceuticals: pharmaceutical drugs, namely pharmaceutical drugs for treatment of skin diseases, antibiotics, immune suppressants, anti-inflammatory pharmaceuticals; pharmaceutical drugs for treatment of disease and disorders of the respiratory system, the gastrointestinal system, the endocrine system, the cardiovascular system, the nervous system, the musculoskeletal system, the urinary system, the integumentary system, the reproductive system, for the treatment of blood diseases and disorders; pharmaceutical and veterinary preparations for treatment of vertigo, migraine, nausea, vomiting, for treatment of skin diseases, and wound healing; pharmaceutical preparations for anti-aging; pharmaceutical preparations namely antibiotics; diagnostic agents for medical use; preparations for medical purposes, namely, for the treatment of skin diseases; substances for medical use, namely, for regeneration of tissue and anti-inflammation; stem cells for medical purposes; stem cells for veterinary purposes; stem cells for aesthetic purposes, namely, for anti-aging, for use in dermatology procedures; somatic stem cell therapeutics, namely, for medical therapeutic use; fibroblasts for medical use; fibroblasts for aesthetic purposes, namely, for use in dermatology procedures; pharmaceutical implants, namely, implantable subcutaneous drug delivery devices sold filled with pharmaceutical for treatment of skin diseases, blood diseases, vertigo, nausea, vomiting, migraine, respiratory system, the gastrointestinal system, the endocrine system, the cardiovascular system, the musculoskeletal system, the urinary system, the integumentary system, and the reproductive system; surgical implants derived from stem cells, namely, surgical implants derived from living tissues and living stem cells; surgical implants derived from fibroblasts, namely, surgical implants comprised of living fibroblasts tissue cells; biological tissue for implantation, namely, implants comprising living tissues; cell growth media for growing cells for medical use; pharmaceutical preparations for tissue regeneration; vascular grafts; living tissue, namely, surgical implants comprised of living tissues; biotechnologically engineered tissue products, namely, living tissue cell sheets and plasters for wound healing and burns, biological eye lens grafts, bone grafts in the nature of biological bone tissue for grafting, biological tissue grafts, human allograft tissue
- Class 042 — Scientific and technological services: Stem cell research; scientific research and development and medical research and development in the field of stem cells, vaccines and medications; scientific research, testing and analysis services in the field of regenerative medicine and tissue engineering, genetics and genetic engineering; scientific research for medical purposes; medical research; research and development of new products for others; consultancy in the field of pharmaceutical research; providing information on medical and scientific research on pharmaceutical products; biomedical research; preparation of reports relating to scientific research, namely, technical writing for others; research in the field of biotechnology; research in the field of gene therapy; research and development in the field of immunology; research and development in the field of antibodies; research and development in the field of antibody technology; research and development in the field of bacteriology; research and development in the field of gene expression systems; research and development in the field of vaccines; research and development services for the pharmaceutical industry; research and development services in the field of biotechnology; development of industrial processes, namely, engineering of industrial processes in the field of for packaging, storage and transport of human tissue and human adult ancestral cells, engineering of industrial processes to manufacture stem cells; industrial process research in the field of regenerative medicine and tissue engineering, chemical engineering
- Class 044 — Medical, beauty and agricultural services: Medical services relating to the removal, treatment, processing and preservation of human cells and tissue, stem cells and bone marrow, also in the field of regenerative medicine, including tissue engineering; medical services in connection with the removal, treatment and processing of human tissue and stem cells, human tissue and stem cell bank services, including in the field of regenerative medicine, including tissue engineering; medical services relating to the cultivation and extraction of stem cells; medical services in connection with the cultivation and extraction of stem cells
Owner
Prosecution history
- 14 Aug 2023 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 20 Jul 2023 — FINAL DISPOSITION NOTICE SENT TO IB
- 20 Jul 2023 — FINAL DISPOSITION PROCESSED
- 04 Jul 2023 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 04 Apr 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 04 Apr 2023 — REGISTERED-PRINCIPAL REGISTER
- 24 Jan 2023 — NOTIFICATION PROCESSED BY IB
- 17 Jan 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Jan 2023 — PUBLISHED FOR OPPOSITION
- 04 Jan 2023 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 04 Jan 2023 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
- 28 Dec 2022 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 15 Dec 2022 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 15 Dec 2022 — EXAMINER'S AMENDMENT ENTERED
- 15 Dec 2022 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED